Evidence map›Paper›PMID 39978161›Full record

ArticleNeuromuscular disorders : NMD2025

Strength and functional correlates of reachable workspace in facioscapulohumeral muscular dystrophy.

Leo H Wang, Maya N Hatch, Michael P McDermott, William B Martens, Katy Eichinger, Leann Lewis, Michaela Walker, Doris G Leung, Kathryn R Wagner, Sabrina Sacconi and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuromuscular disorders : NMD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Leo H WangDepartment of Neurology, University of Washington, WA, USA. Electronic address: leowang@uw.edu.
Maya N HatchDepartment of Physical Medicine & Rehabilitation, University of California Irvine, CA, USA.
Michael P McDermottDepartment of Biostatistics and Computational Biology, University of Rochester Medical Center, NY, USA; Department of Neurology, University of Rochester Medical Center, NY, USA.
William B MartensDepartment of Biostatistics and Computational Biology, University of Rochester Medical Center, NY, USA.
Katy EichingerDepartment of Neurology, University of Rochester Medical Center, NY, USA.
Leann LewisDepartment of Neurology, University of Rochester Medical Center, NY, USA.
Michaela WalkerDepartment of Neurology, University of Kansas Medical Center, KS, USA.
Doris G LeungThe Johns Hopkins School of Medicine, Kennedy Krieger Institute, MD, USA.
Kathryn R WagnerThe Johns Hopkins School of Medicine, Kennedy Krieger Institute, MD, USA.
Sabrina SacconiNeuromuscular disease Department, Referent Center for Rare Neuromuscular Diseases, Nice University Hospital, Nice, France.
Karlien MulDepartment of Neurology, Radboud University Medical Center, Nijmegen, the Netherlands.
Perry B ShiehDepartment of Neurology, University of California, Los Angeles, CA, USA.
Bakri ElsheikhDepartment of Neurology, The Ohio State University Wexner Medical Center, OH, USA.
Russell J ButterfieldUniversity of Utah, UT, USA.
Nicholas E JohnsonDepartment of Neurology, Virginia Commonwealth University, VA, USA.
Valeria SansoneThe NEMO Clinical Center, Neurorehabilitation Unit, University of Milan, Department of Neurology, Milan, Italy.
Jay J HanDepartment of Physical Medicine & Rehabilitation, University of California Irvine, CA, USA.
Rabi TawilDepartment of Neurology, University of Rochester Medical Center, NY, USA.
Jeffrey M StatlandDepartment of Neurology, University of Kansas Medical Center, KS, USA.
ReSolve Investigators of FSHD CTRN

Funding

Clinical Trial Readiness to Solve Barriers to Drug Development in FSHDU01NS101944 · NINDS · UNIVERSITY OF ROCHESTER · PI STATLAND, JEFFREY, TAWIL, RABI · 2017 to 2022
$3.2M
NINDS NIH HHS U01 NS101944
6 · The paper itself

Abstract

Patients with FSHD can develop scapular winging and loss of ability to raise arm. Reachable workspace (RWS) is able to describe upper extremity (UE) reaching ability. We analyzed data from 175 clinically affected and genetically confirmed adults with FSHD enrolled in the Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD (ReSolve) study. Our objective was to 1) investigate the relationship between UE reaching ability and muscle strength (using quantitative muscle testing, QMT); and (2) describe how different reaching abilities correspond to patient-reported function at home. There were strong correlations between total relative surface area (i.e., upper extremity reachability in the frontal plane) and UE strength measured by QMT. For each successive 25 % decrease in total relative surface area, there was a corresponding mean 18 % decrease in predicted UE strength and a mean 9-point decrease in the Upper Extremity Functional Index. Individuals that could not reach the right upper medial quadrant reported more difficulty performing various upper extremity activities of daily living and had decreases in the physical function as reported by the PROMIS-57 questionnaire. RWS provides a meaningful measurement of upper extremity strength and function in patients with FSHD.

Indexed as

Muscle StrengthMuscular Dystrophy, FacioscapulohumeralUpper ExtremityActivities of Daily LivingAdultAgedFemaleHumansMaleMiddle AgedArm strengthBiomarkersFacioscapulohumeral muscular dystrophyPatient reported outcome

Identifiers

PMID39978161
PMCPMC11911083

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.